MARKET

COAG

COAG

HEMAB THERAPEUTICS HOLDINGS
NASDAQ
24.98
-1.96
-7.28%
After Hours: 24.98 0 0.00% 18:26 06/12 EDT
OPEN
26.85
PREV CLOSE
26.94
HIGH
27.00
LOW
24.80
VOLUME
168.76K
TURNOVER
--
52 WEEK HIGH
36.61
52 WEEK LOW
23.00
MARKET CAP
1.17B
P/E (TTM)
-48.6560
1D
5D
1M
3M
1Y
5Y
1D
Jefferies Reiterates Buy on Hemab Therapeutics, Maintains $39 Price Target on VWD Opportunity and Differentiated Mechanism
TipRanks · 4d ago
Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal
TipRanks · 4d ago
Weekly Report: what happened at COAG last week (0601-0605)?
Weekly Report · 4d ago
Weekly Report: what happened at COAG last week (0525-0529)?
Weekly Report · 06/01 10:49
Novo Holdings portfolio company Hemab Therapeutics raises $346.7 million in Nasdaq IPO
PUBT · 06/01 07:53
Hemab Therapeutics Hldgs Price Target Announced at $42.00/Share by Wedbush
Dow Jones · 05/26 17:14
Wedbush Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $42
Benzinga · 05/26 17:03
Hemab Therapeutics Hldgs Price Target Announced at $39.00/Share by Jefferies
Dow Jones · 05/26 16:10
More
About COAG
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets.

Webull offers Hemab Therapeutics Holdings, Inc. stock information, including NASDAQ: COAG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COAG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COAG stock methods without spending real money on the virtual paper trading platform.